Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis

OBJECTIVES: To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). METHODS: Three Spanish cohorts of adults with baseline HIV-RNA <50 copies/mL were harmonized. Multinomial propensity scores were used for 13 baseline variables. Stabilized inverse probability weights were winsorized at the 1st/99th percentiles. The primary outcome was baseline-adjusted CD4+ T-cell count at week 48. Bootstrap confidence intervals and Holm's correction were used. RESULTS: Of 3057 eligible participants, 1794 had complete covariates and 1438 had week-48 CD4+ T-cell counts. B/F/TAF versus DTG/3TC and DTG/RPV differences were -7.4 (95% CI -45.1 to 30.4) and +5.6 (-24.6 to 35.7) cells/μL (both Holm p = 1.000). Additional baseline CD4+ T-cell percentage adjustment changed the former to -39.8 (-78.5 to -1.2). CD4+ T-cell percentage differences were + 1.66 and + 1.44 percentage points (both Holm p ≤ 0.002). Original secondary CD8+ T-cell count differences were - 92.9 and - 96.5 cells/μL (both Holm p = 0.007); the ratio difference versus DTG/3TC was +0.165 (Holm p = 0.013). CONCLUSIONS: In these three Spanish cohorts, the primary propensity score-adjusted analysis did not detect a difference between regimens in the week-48 CD4+ T-cell count. Original secondary analyses associated B/F/TAF with lower CD8+ T-cell counts than both dual regimens and a higher CD4+/CD8+ T-cell ratio than that of DTG/3TC. The CD8+ T-cell count and ratio contrasts versus DTG/3TC attenuated after additional baseline percentage adjustment. These associations were sensitive to baseline immune adjustment, and their clinical relevance warrants further investigation.

Authors

Institutions

Publication Details

Journal
HIV Medicine
Published
2026-11-12
DOI
https://doi.org/10.1111/hiv.70365
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis

Rafael Esteban Micán, Ignacio de los Santos, Julia Gómez, Luís Buzón et al.
HIV Medicine
HIV/AIDS drug development and treatment
article

Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis

Rafael Esteban Micán, Ignacio de los Santos, Julia Gómez, Luís Buzón, Estela Moreno-García, Jesús Troya, Guillermo Pousada, María José Galindo Puerto, José Sanz, Carlos Galera, Carlos J Dueñas, Alberto Díaz de Santiago, Cristina Martín, Miguel Ángel Morán, José Antonio Iribarren
article en

Abstract

OBJECTIVES: To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). METHODS: Three Spanish cohorts of adults with baseline HIV-RNA <50 copies/mL were harmonized. Multinomial propensity scores were used for 13 baseline variables. Stabilized inverse probability weights were winsorized at the 1st/99th percentiles. The primary outcome was baseline-adjusted CD4+ T-cell count at week 48. Bootstrap confidence intervals and Holm's correction were used. RESULTS: Of 3057 eligible participants, 1794 had complete covariates and 1438 had week-48 CD4+ T-cell counts. B/F/TAF versus DTG/3TC and DTG/RPV differences were -7.4 (95% CI -45.1 to 30.4) and +5.6 (-24.6 to 35.7) cells/μL (both Holm p = 1.000). Additional baseline CD4+ T-cell percentage adjustment changed the former to -39.8 (-78.5 to -1.2). CD4+ T-cell percentage differences were + 1.66 and + 1.44 percentage points (both Holm p ≤ 0.002). Original secondary CD8+ T-cell count differences were - 92.9 and - 96.5 cells/μL (both Holm p = 0.007); the ratio difference versus DTG/3TC was +0.165 (Holm p = 0.013). CONCLUSIONS: In these three Spanish cohorts, the primary propensity score-adjusted analysis did not detect a difference between regimens in the week-48 CD4+ T-cell count. Original secondary analyses associated B/F/TAF with lower CD8+ T-cell counts than both dual regimens and a higher CD4+/CD8+ T-cell ratio than that of DTG/3TC. The CD8+ T-cell count and ratio contrasts versus DTG/3TC attenuated after additional baseline percentage adjustment. These associations were sensitive to baseline immune adjustment, and their clinical relevance warrants further investigation.

HIV Medicine
Hospital Universitario La Paz (ES), Hospital Clínico Universitario de Valencia (ES), Complejo Hospitalario de Navarra (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Txagorritxu (ES), Hospital Universitario Príncipe de Asturias (ES), Hospital Universitario de Burgos (ES), Hospital Universitario de La Princesa (ES), Donostiako Unibertsitate Ospitalea (ES), Hospital Universitario Virgen de la Arrixaca (ES), Hospital Clínico Universitario de Valladolid (ES), Hospital Universitario Río Hortega (ES), Hospital Universitario Infanta Leonor (ES)
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon